Search

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

The glamorous life of parenthood and medicine

The glamorous life of parenthood and medicine

By Ana Zelić Kerep, MD (YoungEHA Ambassador)

Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

Meet Irene Roberts, our September volunteer of the month

Can you tell us what you do for EHA and when you started?
I joined EHA in 2003 and shortly afterwards I was lucky enough to be elected as a member of the EHA Board.

Read more

Practical information

When do the meetings take place?
CRTH 2025 timeline is as follows:

Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.

Read more

Burnouts: when caregivers become patients

Author: Côme Bommier (Young EHA Ambassador)
Affiliations: Hôpital St-Louis (Paris, France) & Mayo Clinic (Rochester MN, USA)

A survey will be released in September to further map burnout
among hematology professionals in Europe.

Read more

Challenging the safety of conformity: Better poster design to disseminate scientific knowledge fast

“Congratulations – your abstract was accepted for the upcoming EHA congress”.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more